ArriVent BioPharma (AVBP) Stock Forecast, Price Target & Predictions
AVBP Stock Forecast
ArriVent BioPharma stock forecast is as follows: an average price target of $35.67 (represents a 36.72% upside from AVBP’s last price of $26.09) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
AVBP Price Target
The average price target for ArriVent BioPharma (AVBP) is $35.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $35.00. This represents a potential 36.72% upside from AVBP's last price of $26.09.
AVBP Analyst Ratings
According to 3 Wall Street analysts, ArriVent BioPharma's rating consensus is 'Buy'. The analyst rating breakdown for AVBP stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ArriVent BioPharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Yigal Nochomovitz | Citigroup | $36.00 | $27.93 | 28.92% | 37.98% |
| Sep 10, 2024 | Robert Burns | H.C. Wainwright | $36.00 | $28.04 | 28.41% | 37.98% |
| Aug 16, 2024 | Robert Burns | H.C. Wainwright | $30.00 | $23.62 | 27.01% | 14.99% |
| Jul 22, 2024 | Jeff Jones | Oppenheimer | $35.00 | $18.77 | 86.47% | 34.15% |
The latest ArriVent BioPharma stock forecast, released on Sep 10, 2024 by Yigal Nochomovitz from Citigroup, set a price target of $36.00, which represents a 28.92% increase from the stock price at the time of the forecast ($27.93), and a 37.98% increase from AVBP last price ($26.09).
ArriVent BioPharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $34.25 |
| Last Closing Price | $26.09 | $26.09 | $26.09 |
| Upside/Downside | -100.00% | -100.00% | 31.28% |
In the current month, the average price target of ArriVent BioPharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ArriVent BioPharma's last price of $26.09. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 10, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 22, 2024 | Oppenheimer | Outperform | Initialise |
ArriVent BioPharma's last stock rating was published by Citigroup on Sep 10, 2024. The company gave AVBP a "Buy" rating, the same as its previous rate.
ArriVent BioPharma Financial Forecast
ArriVent BioPharma Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
ArriVent BioPharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVBP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ArriVent BioPharma EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict AVBP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ArriVent BioPharma's previous annual EBITDA (undefined) of $NaN.
ArriVent BioPharma Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
ArriVent BioPharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVBP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ArriVent BioPharma SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
ArriVent BioPharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AVBP last annual SG&A of $NaN (undefined).
ArriVent BioPharma EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, ArriVent BioPharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AVBP previous annual EPS of $NaN (undefined).